FDA Skips Advisory Committee For Capricor's Duchenne Cell Therapy

Why did stocks rise and oil fall after Israel-Iran ceasefire? How did Fed's Powell respond to Trump on interest rates? What caused CareerBuilder + Monster bankruptcy? Why is Tesla's robotaxi facing regulatory scrutiny? How will Kroger's store closures impact the retail sector? What are the effects of proposed Medicaid cuts on hospitals? Why did Disney lay off tech and product staff again?

FDA Skips Advisory Committee For Capricor's Duchenne Cell Therapy

benzinga.com/news/fda/25/06/46081450/fda-skips-advisory-committee-for-capricors-duchenne-cell-therapy

Capricor Therapeutics Inc (NASDAQ:CAPR) on Tuesday provided regulatory updates related to its Biologics License Application (BLA) for Deramiocel, the company’s lead cell therapy candidate for the treatment of Duchenne Muscular Dystrophy (DMD)—associated cardiomyopathy.
DMD is an X-linked…

This story appeared on benzinga.com, 2025-06-24 18:51:31.